金樱子提取液对糖尿病肾病大鼠的肾脏保护作用

目的:研究金樱子提取液对糖尿病肾病(Diabetic Nephropathy,DN)大鼠的肾脏保护作用。方法:在高糖高脂饲料喂食SD(Sprague-Dawley)大白鼠的基础上腹腔注射链脲佐菌素(streptozotocin,STZ)诱导糖尿病肾病大鼠模型,随机分为糖尿病肾病模型组(DN组)和金樱子治疗组(DN+RLM组),同时另设正常对照组(NC组)和金樱子对照组(NC+RLM组)。检测金樱子提取液对各组大鼠血糖(fasting blood-glucose,FBG)、糖化血红蛋白(glycosylated haemoglobin,GHb)、24小时尿微量白蛋白和尿量、血尿素氮(BUN)、血肌酐(Scr)、胆固醇(TC)、甘油三酯(TG)及肾脏结构的影响。结果:与DN大鼠相比,糖尿病肾病大鼠经金樱子提取液治疗后,大鼠FBG、GHb水平、24 h尿微量白蛋白、24 h尿量、肾脏指数明显降低,血脂紊乱、肾功能损害以及DN肾脏病理明显改善,且无明显副作用。结论:金樱子提取液可明显降低DN大鼠血糖,改善DN大鼠血脂、肾功能紊乱及肾脏病理变化,对糖尿病大鼠肾脏具有较强的保护作用。     

金樱子资源的开发利用

金樱子资源的开发利用顾志平,张曙明,刘东（中国医学科学院药用植物资源开发研究所北京１０００９４）金樱子（ＢｏｓａｌｅａｖｉｇａｔａＭｉｃｈｘ．）是蔷薇科蔷薇属植物,果富含维生素,民间早有食用习惯,亦为我国较常用的中药,历史悠久,现代研究表明,金樱子有...     

中药金樱子的化学成分

从中药金樱子（Rosa laevigata Michx.）的果实是分离到7个化合物,经理化性质和波谱分析分别确定为β－谷甾醇（1）、胡萝卜甙（2）、乌苏酸（3）、2α,3β,19α,23－四羟基乌苏－12－烯－28酸（4）,2α,3β,19α,23－四羟基乌苏－12－烯－28酸28－O-β-D-吡喃葡萄糖苷（5）,2α,3β,19α,23－三羟基乌苏－12－烯－28酸（6）和4',5,7－三羟黄酮醇－3－O－β-D-（6”－O－（E）－p－羟基苯丙烯酰）吡喃葡萄糖苷（7）,其中化合物4、5、7为首次从金樱子果实中分离得到。     

保健野果金樱子

金樱子(Rosa laevigata)是蔷薇科、蔷薇属 的常绿攀援灌木,在我国分布极广,华东、华南、 华中、西南诸省区均有。在安徽省,金樱子主要 分布于皖南山区和大别山区,尤以海拔500米 以下的低山丘陵的山崖石隙及阳坡灌丛中多 见。植株结果数量多、产量高,据初步样方调查 及产地近年的收购(药用)记录估计,仅皖西的 金寨、霍山、舒城及六安等县市,年产量可达 600—800吨。     

金樱子多糖的抗氧化作用

目的：探讨金樱子多糖(PRL)体外抗氧化作用。方法：邻苯三酚自氧化法测定PRL清除超氧阴离子自由基效果;比色法测定PRL对羟自由基诱导红细胞溶血、脂质过氧化反应的影响。结果：PRL能显著清除超氧阴离子自由基、押制羟自由基对细胞膜的破坏而引起的溶血和脂质过氧化产物的形成。结论：PRL具有显著的抗氧化作用。     

大鼠咬合创伤牙周膜中MCP-1、ICAM-1的表达变化

目的:研究咬合创伤大鼠牙周组织中MCP-1、ICAM-1的表达情况。方法:12周龄雄性SD大鼠24只,随机分为4组(1个正常对照组和3个实验组),每组6只。正常对照组不作任何处理,实验组通过在大鼠左上颌第一磨牙颌面粘接树脂并内置不锈钢丝形成高出颌面0.6-0.8 mm的树脂层以建立同侧下颌咬合创伤实验动物模型,分别于建模后3、5、7 d处死各组大鼠,分离大鼠下颌组织,运用HE、Masson染色观察咬合创伤牙周组织形态变化,同时用免疫组织化学染色法检测MCP-1和ICAM-1的表达变化。结果:HE染色显示,正常组牙周膜纤维排列整齐,牙骨质表面较为平整,牙槽骨结构致密。实验组牙周膜纤维排列紊乱,牙周膜血管水肿充血、间隙改变,牙槽骨和牙骨质表面不平整,出现骨吸收。Masson染色显示,正常组牙周组织未见异常表现;实验组牙周膜纤维排列紊乱,可见水解断裂,局部有血流障碍和血管破裂。免疫组织化学显示,各实验组MCP-1和ICAM-1的表达变化均较正常对照组增多,差异有显著性(P0.05)。其中7 d组表达水平最高,与其他2组相比有统计学意义(P0.05)。结论:咬合创伤可引起大鼠牙周组织形态变化,MCP-1、ICAM-1的表达随时间呈现递增的趋势。     

金樱子多糖的抑菌和抗炎作用研究

研究了金樱子多糖的抗菌活性和抗炎作用。实验表明:金樱子多糖具有一定的抑菌活性,如对大肠杆菌、副伤寒杆菌、白葡萄球菌以及金黄色葡萄球菌等均有较强的抑制作用;能抑制二甲苯引起小鼠的耳肿胀,与NS组比较有明显差异(P<0.01),具有一定的抗炎作用。     

中药金樱子的研究应用概况

本文就国内外对中药金樱子的化学成分及其提取分离方法、药理学研究和临麻应用作了综述,为金樱子的综合开发提供依据。     

糖尿病大鼠肾皮质ICAM-1在缬沙坦作用后表达的变化研究

目的：利用血管紧张素I（IAngII）受体拮抗剂缬沙坦（Valsartan）阻断肾素-血管紧张素（RAS）观察其对糖尿病大鼠肾皮质细胞间粘附分子-1（ICAM-1）表达的影响。方法：成年雄性SD大鼠45只,任取其中30只腹腔注射链脲佐菌素制成糖尿病大鼠模型。将糖尿病大鼠随机分为糖尿病缬沙坦治疗组（A组,15只,缬沙坦10mg.kg-1/d灌胃）;糖尿病对照组（B组,15只）;其余15只为正常对照组（C组）。分别于实验第4、6周末各组任取7或8只测定大鼠血糖、平均动脉压、血肌酐、尿肌酐、尿白蛋白排泄率,用图像分析仪测量各组大鼠平均肾小球面积、平均肾小球体积。并于第6周末取各组大鼠肾皮质提取RNA,用逆转录-PCR（RT-PCR）方法对肾皮质ICAM-1mRNA表达进行半定量分析。结果：在第4周及第6周末,A组血糖、肌酐清除率、尿白蛋白排泄率显著低于同时期的B组,B组则较C组均有不同程度的升高（P〈0.01）,A、C组尿白蛋白排泄率始终无统计学差异,同时期三组平均动脉压无统计学差异（P〉0.05）。在4、6周,A、B组的肾小球平均面积、平均体积均明显高于同期的C组（P〈0.01）,但A组又低于同期的B组。RT-PCR半定量结果分析显示,B组ICAM-1 mRNA表达较A、C组显著增高（P〈0.01）,A组表达较C组为高（P〈0.01）,但仍较B组为低（P〈0.01）。结论：血管紧张素I（IAngII）受体拮抗剂缬沙坦能够减少糖尿病大鼠的尿白蛋白排泄,下调肾皮质ICAM-1mRNA表达,减轻肾脏肥大及延缓肾小球硬化,具有保护肾脏的作用。     

黄芪调节自发糖尿病肾病鼠层粘连蛋白表达的实验研究

目的:观察黄芪对自发糖尿病肾病大鼠肾小球层粘连蛋白表达的影响.方法:将实验用6月龄SPF级GK大鼠和Wistar大鼠随机分为正常对照组、糖尿病组、黄芪治疗组.治疗16周,观察治疗后大鼠的尿素氮、血肌苷,内生肌苷清除率、24小时尿蛋白排泄率,免疫组化检测肾组织层粘连蛋白表达.结果:造模组大鼠均出现肾脏功能有损害.黄芪能改善自发糖尿病肾病大鼠基本状况,降低糖尿病大鼠的尿素氮、血肌苷、24h尿白蛋白排泄率,增加内生肌苷清除率,层粘连蛋白表达显著下调.结论:黄芪可通过降低层粘连蛋白的表达,对肾脏起保护作用.     

Paeoniflorin Prevents Diabetic Nephropathy in Rats

The aim of this study was to test the hypothesis that paeoniflorin prevents the progression of diabetic nephropathy by modulating the inflammatory process. Sprague–Dawley rats were divided into 5 groups: nondiabetic control rats; untreated diabetic model (DM) rats; and DM rats treated with 5, 10, or 20 mg/kg paeoniflorin in drinking water once daily. Rats received a single intravenous injection of streptozotocin to induce diabetes; 9 wk after injection, rats began the 8-wk daily paeoniflorin treatment regimen. Compared with that of nonDM controls, the urinary albumin:creatinine ratio was increased significantly in untreated DM rats; this ratio was decreased in DM rats treated with 5, 10, or 20 mg/kg paeoniflorin compared with that of untreated DM rats. In addition, paeoniflorin treatment effectively suppressed glomerular hypertrophy; blood glucose; the expression of transforming growth factor β, type IV collagen, and intercellular adhesion molecule 1; and renal infiltration of macrophages compared with levels in untreated DM rats. Furthermore, renal nuclear factor κB activity was increased in untreated but not paeoniflorin-treated DM rats. In conclusion, our data suggest that the preventive effects of paeoniflorin may be mediated by its antiinflammatory actions.Abbreviations: DM, diabetic model; ECM, extracellular matrix; ICAM1, intercellular adhesion molecule 1; MCP1, monocyte chemoattractant protein 1; NFκB, nuclear factor κB; TGFβ, transforming growth factor βDiabetic nephropathy is the most common cause of endstage renal disease and high mortality in humans. Adequate control of blood glucose may slow the rate of its progression, but it is still difficult to achieve strict glycemic control for diabetic patients in the longer term, due at least in part to the limitations of available therapeutic approaches.³ Recent studies have suggested the emerging role of inflammatory processes in the pathogenesis of diabetic nephropathy in addition to other well-known mechanisms.In human renal disease, transforming growth factor β (TGFβ) may mediate the buildup of tissue extracellular matrix (ECM) proteins.¹⁷ This cytokine reportedly stimulated ECM protein accumulation in diabetic tissues by upregulating the production of ECM proteins or by downregulating the production of ECM-degrading enzymes.²⁶ Renal levels of TGFβ1 increase in both experimental and human diabetes. In addition, TGFβ1 induces the synthesis of ECM components including collagen types I, III, and IV and fibronectin.^2,5Intercellular adhesion molecule 1 (ICAM1) is a key adhesion molecules. In addition, the ICAM1-dependent infiltration of macrophages into the kidney is very important in the pathogenesis of diabetic nephropathy.¹⁸ In addition, the expression of ICAM1 is rapidly induced and maintained for a long time in renal tissues after induction of diabetes in experimental type 1 diabetic rats.^14,20 Macrophage infiltration was blocked by antiICAM1 antibody, confirming that ICAM1 mediates macrophage infiltration into the diabetic kidney.⁶ Furthermore, ICAM1-deficient mice were protected from renal injury after the induction of diabetes, suggesting that the inflammatory process is a critical factor for the development of diabetic nephropathy.²¹Despite the availability of treatments that lower blood glucose and blood pressure, many diabetic patients are still prone to developing kidney failure, which no currently available therapies can reverse.²⁴ Therefore a search is needed for new therapeutic approaches—based on novel mechanisms of action—to the treatment of diabetic nephropathy. Paeoniflorin is a monoterpene glucoside and a component of the total glucoside extract obtained from the root of Paeonia lactiflora.²⁸ This extract was approved for marketing in China in 1998.²³ As a disease-modifying drug, the total glucoside extract of peony has both antiinflammatory and immune-regulatory effects and is used in the treatment of rheumatoid arthritis, hepatitis, systemic lupus erythematosus, and mesenteric hyperplastic nephritis.^8,9,27 The goal of this study is to address whether paeoniflorin might prevent the progression of diabetic nephropathy through the inhibition of the inflammatory processes including TGFβ, type IV collagens, and ICAM1 expression, monocyte chemoattractant protein 1 (MCP1), nuclear factor κB (NFκB) activation, and macrophage infiltration.     

Therapeutic Effects of Tangshen Formula on Diabetic Nephropathy in Rats

Objective

Inflammation and fibrosis are essential promoters in the pathogenesis of diabetic nephropathy (DN) in type 2 diabetes. The present study examined the anti-inflammation and anti-fibrosis effect of Tangshen Formula (TSF), a traditional Chinese medicine, on DN.

Research Design and Methods

Protective role of TSF in DN was examined in a rat model of type 2 DN that was established by high-fat diet-fed and low-dose-streptozotocin injection. TSF was suspended in 0.5% CMC-Na solution and delivered by oral gavage at a dosage of 1.67g/Kg body weight/day. The therapeutic effects and mechanisms of TSF on diabetic kidney injury were examined.

Results

We found that TSF treatment for 20 weeks attenuated DN by significantly inhibiting urinary excretion of albumin and renal histological injuries. These beneficial effects were associated with an inactivation of NF-κB signaling, thereby blocking the upregulation of pro-inflammatory cytokines (IL-1β, TNFα), chemokine (MCP-1), and macrophage infiltration in the TSF-treated rats with type 2 DN. In addition, TSF treatment also inactivated TGF-β/Smad3 signaling and therefore suppressed renal fibrosis including expressions of fibronectin, collagen I, and collagen IV. Further studies revealed that the inhibitory effect of TSF on TGF-β/Smad3 and NF-κB signaling in DN was associated with inhibition of Smurf2-dependent ubiquitin degradation of Smad7.

Conclusions

The present study reveals that TSF has therapeutic potential for type 2 DN in rats. Blockade of NF-κB-driven renal inflammation and TGF-β/Smad3-mediated renal fibrosis by preventing the Smurf2-mediated Smad7 degradation pathway may be mechanisms through which TSF inhibits type 2 DN.     

C肽对糖尿病大鼠肾脏的影响

比较C肽和胰岛素对大鼠糖尿病肾病的治疗作用。方法:选取Wistar大鼠40只,分为正常对照组(NG组)和糖尿病组(DM组),糖尿病组链脲佐菌素诱发大鼠成模后,随机分为三组:糖尿病组(DM组)、胰岛素组(IG组)和C肽组(ICG组)。治疗8周后测定各组大鼠24小时尿白蛋白排泄率(UAER)、肾重/体重,并观察糖尿病大鼠肾脏超微结构变化。结果:24小时尿白蛋白排泄率:糖尿病组明显增加,C肽组明显低于糖尿病组和胰岛素组,差异具有显著性。大鼠肾脏超微结构变化:各组大鼠肾小球截面积、肾小球平均体积(MGV)、细胞外基质/肾小球截面积比值、细胞外基质截面积、肾小球基底膜厚度相比,糖尿病组明显升高,C肽组较胰岛素组和糖尿病组明显下降,差异具有显著性。结论:C肽治疗可以降低24小时尿白蛋白排泄率,改善糖尿病大鼠肾脏超微结构病变。     

亚硒酸钠对糖尿病肾病大鼠肾脏Nephrin表达的影响与意义

探讨亚硒酸钠对糖尿病肾病大鼠肾脏Nephrin表达的影响及二者间的关系,从而研究亚硒酸钠和Nephrin在糖尿病肾病中的作用机制.通过链脲佐菌素法及给予高脂饮食诱导模拟大鼠糖尿病肾病模型,实验设空白对照组、糖尿病肾病对照组、亚硒酸钠干预组,亚硒酸钠干预组每日给予亚硒酸钠溶液灌胃,其它组给予等量生理盐水灌胃.灌胃10周后处死大鼠,取血、尿标本测相关生化指标.取肾脏组织戊二醛固定制作切片电镜下观察超微结构改变,取肾脏组织多聚甲醛固定制石蜡切片光镜下观察病理改变和免疫组化定位蛋白表达.取肾脏组织RT-PCR检测Nephrin的mRNA表达、Western Blotting检测nephrin的蛋白表达,分析各组数据的统计差异.结果发现亚硒酸钠干预组大鼠基本状况和生化指标较糖尿病肾病对照组明显改善,光镜和电镜下观察病理改变和超微结构病变较糖尿病肾病对照组明显减轻.免疫组化nephrin蛋白表达着色糖尿病肾病对照组较空白对照组减少,亚硒酸钠干预组较糖尿病肾病对照组着色明显增多.Nephrin mRNA和蛋白表达糖尿病肾病对照组较空白对照组明显降低,而亚硒酸钠干预组较糖尿病肾病对照组升高,但低于空白对照组,差异均有统计学意义（P〈0．05）．亚硒酸钠明显促进肾脏Nephrin表达,改善了糖尿病肾病,表明亚硒酸钠和Nephrin在防治和延缓糖尿病肾病的发生发展中可能起重要作用．     

缬沙坦治疗糖尿病肾病疗效观察

目的观察血管紧张素Ⅱ1型受体拮抗剂(AT1Ra)缬沙坦(Valsartan)对伴大量白蛋白尿的临床糖尿病肾病的治疗作用.方法 32例2型糖尿病患者,24h尿白蛋白排泄率(24hUAER)＞200μg/min,均伴高血压,维持原糖尿病治疗不变,分组比较应用缬沙坦(80 mg/d)或贝那普利(10 mg/d)治疗8周前后平均动脉压(MAP)、24h UAER、HbA1c、尿酸(UA)等指标的变化.结果缬沙坦治疗组和贝那普利治疗组24h UAER分别由(703.2±987.9)μg/min降至(664.2±970.6)μg/min(P＜0.01)和由(778.6±1005.0)μg/min降至(734.9±996.0)μg/min(P＜0.01).二者疗效相似,且均与血压变化不相关.结论AT1Ra缬沙坦可以降低临床糖尿病肾病的尿蛋白,其肾脏保护作用除了与降血压有关,还有不依赖降压效应的其他机制.     

The Diabetic Nephropathy and the Development of Hypertension in Rats

The present study was designed to examine the development of hypertension in diabetic rats treated with streptozotocin (STZ, 1mg/g bw). The rats were studied at 3, 6, 9, 12 and 15 weeks. From the third week the rats were divided in diabetic rats according their glycemias and controls, along 15 weeks. After the third week a group, of rats showed increased urinary protein excretion (93, 134, 155 and 191%) compared to controls. In this group of rats the urinary kallikrein excretion was lower than control and the systolic blood pressure became significantly elevated between 3 and 6 weeks and persisted up to 15 weeks. On the other hand a group of diabetic rats were normotensive with urinary protein excretion similar to controls and urinary kallikrein lower compared to control but significantly higher compared diabetic hypertensive rats. These data suggest that the association of progressive diabetic nephropathy with abnormal endothelium-dependent vasodilation may produce a high prevalence of hypertensive diabetes.     

Effect of a Low-Protein Diet Supplemented with Ketoacids on Skeletal Muscle Atrophy and Autophagy in Rats with Type 2 Diabetic Nephropathy

A low-protein diet supplemented with ketoacids maintains nutritional status in patients with diabetic nephropathy. The activation of autophagy has been shown in the skeletal muscle of diabetic and uremic rats. This study aimed to determine whether a low-protein diet supplemented with ketoacids improves muscle atrophy and decreases the increased autophagy observed in rats with type 2 diabetic nephropathy. In this study, 24-week-old Goto-Kakizaki male rats were randomly divided into groups that received either a normal protein diet (NPD group), a low-protein diet (LPD group) or a low-protein diet supplemented with ketoacids (LPD+KA group) for 24 weeks. Age- and weight-matched Wistar rats served as control animals and received a normal protein diet (control group). We found that protein restriction attenuated proteinuria and decreased blood urea nitrogen and serum creatinine levels. Compared with the NPD and LPD groups, the LPD+KA group showed a delay in body weight loss, an attenuation in soleus muscle mass loss and a decrease of the mean cross-sectional area of soleus muscle fibers. The mRNA and protein expression of autophagy-related genes, such as Beclin-1, LC3B, Bnip3, p62 and Cathepsin L, were increased in the soleus muscle of GK rats fed with NPD compared to Wistar rats. Importantly, LPD resulted in a slight reduction in the expression of autophagy-related genes; however, these differences were not statistically significant. In addition, LPD+KA abolished the upregulation of autophagy-related gene expression. Furthermore, the activation of autophagy in the NPD and LPD groups was confirmed by the appearance of autophagosomes or autolysosomes using electron microscopy, when compared with the Control and LPD+KA groups. Our results showed that LPD+KA abolished the activation of autophagy in skeletal muscle and decreased muscle loss in rats with type 2 diabetic nephropathy.